Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 8/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600291 | 0.92 | GRIN2B (0.55) | GRIN2BNPY5RPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL3596258 | 0.90 | NPC1 (0.47) | GRIN2BNPY5RFAAHNTSR1RAB9A | |
| SCHEMBL3602171 | 0.84 | KDM4E (0.43) | GRIN2BNPY5RFAAHNTSR1POLB | |
| SCHEMBL3600784 | 0.84 | GRIN2B (0.48) | GRIN2BNPY5RNTSR1POLB | |
| SCHEMBL3598451 | 0.83 | ALDH1A1 (0.45) | GRIN2BNTSR1POLBSMN1; SMN2 | |
| SCHEMBL3601361 | 0.82 | KDM4E (0.44) | GRIN2BNPY5RFAAHPOLBSMN1; SMN2 | |
| SCHEMBL3597368 | 0.82 | TSHR (0.46) | GRIN2BNPY5RPOLBRAB9A | |
| SCHEMBL3602467 | 0.82 | KDM4E (0.46) | GRIN2BNPY5RPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL3644326 | 0.82 | KDM4E (0.48) | GRIN2BPOLBSMN1; SMN2 | |
| SCHEMBL3600113 | 0.82 | GRIN2B (0.44) | GRIN2BNPY5RPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007115231-A2 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | GRIN2B 2950/4885NPY5R 4199/4885FAAH 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.